Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].

Details

Serval ID
serval:BIB_6A4C636AAB5B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Journal
Revue Médicale Suisse
Author(s)
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2011
Volume
7
Number
296
Pages
1126-1130
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
Melanoma is the cancer with the fastest incidence increase in Switzerland. 30% of the cases arise before the age of 50 years. Once metastatic, the median survival under current systemic therapies is about 8 months, with less than 5% of patients alive at 5 years. Many efforts in the understanding of cellular biology, intracellular signaling pathways, as well as the role of cellular immunity have been made in the recent years. This has resulted in the development of novel and very promising therapies. In this review, we will cover the results obtained with targeted therapies such as "tyrosin kinase inhibitors" (TKI), as well as those obtained with a monoclonal antibody directed against the CTLA-4 receptor of lymphocytes.
Keywords
Antibodies, Monoclonal/therapeutic use, Antigens, CD/drug effects, Antineoplastic Agents/therapeutic use, CTLA-4 Antigen, Enzyme Inhibitors/therapeutic use, Humans, Immunosuppressive Agents/therapeutic use, Incidence, Melanoma/drug therapy, Melanoma/epidemiology, Protein-Tyrosine Kinases/antagonists & inhibitors, Skin Neoplasms/drug therapy, Skin Neoplasms/epidemiology, Survival Rate, Switzerland/epidemiology
Pubmed
Create date
06/09/2011 10:44
Last modification date
20/08/2019 14:25
Usage data